• Target

    £5,000,000

  • Type

    Equity

  • Close Date

    Sep 7 2018

  • Status

    Live

RISK WARNING: Your capital is at risk. The risks include: the lack of liquidity in this market in terms of being able to sell shares; the loss of the value of investment; and dilution of shareholding. When you invest any loss in value will not be covered by the Financial Services Compensation Scheme. Please read FULL risk warning.

Lightpoint Medical

Lightpoint Medical is an innovative medical device company dedicated to improving health outcomes for cancer patients through image-guided surgery.

Investment closes only once the total pledged amount passes the minimum of £4,000,000

Total Pledged: £4,500,000
Max

£5,000,000

A pledge is not a commitment. You will be asked to confirm in the next section.

Track
Contact
Companies
House
Twitter

Overview

Lightpoint medical is a growth-stage and revenue generating medical device company founded in 2012 by Dr David Tuch, a highly experienced scientist specialising in medical imaging and pharmaceutical sectors.. Lightpoint was formed to address a widespread medical problem faced by cancer patients, namely, that cancer surgery is very often unsuccessful. Cancer surgery is frequently unsuccessful for the simple reason that surgeons cannot see cancer during surgery. Cancer surgeons are completely reliant on their sense of touch and naked eye. Lightpoint develops and markets medical imaging technologies that surgeons can use during surgery to find the cancer and improve the outcome of the surgery.
 
The company has four products under various stages of development: The LightPath® Imaging System (CE marked) for imaging surgical specimens and is in the early sales stage, the PICO™ laparoscopic probe for minimally-invasive prostate surgery (under development), HARLI™ for the life sciences market (launched), and Clovis (under development) for open surgery. The company’s products address the pressing medical need for better tools to detect cancer during surgery in order to improve clinical outcomes and reduce healthcare costs. Whilst the technology is applicable across a wider number of cancer types, Lightpoint Medical’s focus is on prostate and breast cancer surgery.
 
Lighpoint is now seeking investment of £5m in it’s series B funding round to further enhance product development, increase the number of sales and marketing distribution channels and to cover clinical expense. 
 
Deal Manager avatar

Deal Manager
Agne Pakalniskyte

  • Sector: Healthcare
  • Region: UK: South-East
  • Stage: Early stage - early revenues, pre-profit
  • Eligible Tax: EIS
  • Board Requirement: Board In Place
  • Pre Money Valuation: £15,000,000
This section is currently locked.
Please Sign Up or Log In to unlock.

Team

This section is currently locked.
Please Sign Up or Log In to unlock.

Market

This section is currently locked.
Please Sign Up or Log In to unlock.

Investment

This section is currently locked.
Please Sign Up or Log In to unlock.

Discussions

This section is currently locked.
Please Sign Up or Log In to unlock.

Deal documents

This section is currently locked.
Please Sign Up or Log In to unlock.